#1

Rapamycin is the best-characterized autophagy inducer, which is related to its antiaging and neuroprotective effects…

Since rapamycin’s neuroprotective effect in a Parkinson’s disease (PD) model was observed at 7 weeks of treatment; we evaluated its effect on the liver, kidney, pancreas, and spleen. In addition, we prolonged treatment with rapamycin for 14 weeks. Tissue sections were subjected to histochemical, immunodetection, and morphometric analysis. Chronic rapamycin administration does not affect bodyweight, survival, and liver or kidney morphology. Although the pancreas tissular architecture and cellular distribution in Langerhans islets are modified, they may be reversible. The spleen B lymphocyte and macrophage populations were decreased. Notably, the lymphocyte T population was not affected. Therefore, chronic administration of a rapamycin neuroprotective dose does not produce significant tissular alterations. Our findings support the therapeutic potential of rapamycin as a neuroprotective agent.

Research Paper:

1 Like
#2

I haven’t found full access paper yet, but another in vivo amazing study!

What I’m looking for is the data supporting “neuroprotection”…what brain data do they have??

#3

Here’s paper, author sent it on request

2022 Naunyn-Schmiedeberg’s Archives of Pharmacology.pdf (3.5 MB)

2 Likes
#4

Does anyone know how does the dosage in mice translate to humans? If I’m reading correctly, in the study they administered 1mg/KG 3x weekly…?